But when he divided the women according to whether they took bevaciumab or not, there was a significant difference in the time they were disease-free, which is how treatment effectiveness is measured. The 16% of women in the study who did nottake bevacizumab and had weekly ovarian cancer chemotherapy had 14.2 months without signs of their ovarian cancer progressing, compared to 10.3 months for those getting monthly ovarian cancer chemotherapy.
That suggests, says Chan, that somehow the bevacizumab was having a different effect when the ovarian cancer chemotherapy was more frequent than on the monthly schedule. He suspects that with the weekly dosing, the bevacizumab and paclitaxel, which, like bevacizumab, also discourages blood vessel formation, are somehow competing with and canceling each other out. “My hope was that the bevacizumab combined with the weekly paclitaxel would be synergistic or additive,” he says. “We would have two drugs that both hit the blood vessels for ovarian cancer, which is a very [blood-vessel dependent] cancer, to knock it down.” source
Prev2 of 2Next
Continue Reading on Next Page